Sakshi Gulati

Oncology R&D, AstraZeneca
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High CST2 Expression and a Favorable Prognosis.

Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High CST2 Expression and a Favorable Prognosis.

Journal: Cancer research communications
Published: March 14, 2025

Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma.

Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma.

Journal: Cancer research communications
Published: April 12, 2023

Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.

Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.

Journal: Nature medicine
Published: June 05, 2020

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

Journal: The Lancet. Oncology
Published: February 28, 2020

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.

Journal: Nature medicine
Published: July 09, 2019

Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer.

Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer.

Journal: Scientific reports
Published: April 08, 2019

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study.

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study.

Journal: Nature medicine
Published: August 10, 2018

Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics.

Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics.

Journal: British journal of pharmacology
Published: June 21, 2018

The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.

The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 22, 2017

Relapse models for clear cell renal carcinoma.

Relapse models for clear cell renal carcinoma.

Journal: The Lancet. Oncology
Published: June 05, 2015

Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.

Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.

Journal: European urology
Published: April 30, 2014

Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.

Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.

Journal: Genome biology
Published: April 28, 2014
Showing 1-12 of 15

Last Updated: 09/26/2026